GlassScriptPhysician profile
Shaun Hampton
NPI 1093261497
$5,254.43
in general payments reported to CMS, 2019-2025
30 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $1,888 · 2023: $1,207 · 2024: $327 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,340.24 | 2021-2024 | Proclaim, Prodigy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $901.88 | 2021-2025 | Relistor |
| Abbvie INC. | $723.85 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $428.33 | 2021-2023 | Xtampza, Belbuca |
| Valinor Pharma, LLC | $360.13 | 2023-2025 | Movantik |
| Boston Scientific Corporation | $245.46 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $207.25 | 2021-2023 | Ztlido |
| Amgen INC. | $155.63 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $129.19 | 2021 | |
| Redhill Biopharma INC. | $100.19 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $93.71 | 2022-2023 | Trudhesa |
| Hikma Pharmaceuticals USA | $79.63 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $68.38 | 2021 | |
| Impel Pharmaceuticals LLC | $50.47 | 2025 | Trudhesa |
| Allergan, INC. | $41.28 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $36.47 | 2021 | |
| Bioventus LLC | $33.22 | 2021-2023 | Gelsyn-3 |
| Averitas Pharma INC. | $32.25 | 2023 | Qutenza |
| Lilly USA, LLC | $27.02 | 2022 | |
| Upsher-Smith Laboratories LLC | $23.06 | 2021 | |
| Pfizer INC. | $22.17 | 2023 | |
| Vertos Medical, INC. | $20.67 | 2023 | Mild Device Kit |
| Horizon Therapeutics Plc | $20.57 | 2021 | |
| Ibsa Pharma INC. | $19.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2021 | |
| Grt US Holding, INC. | $19.41 | 2021 | |
| Stratus Medical, LLC | $14.41 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.11 | 2023 | Lyvispah |
| Virtus Pharmaceuticals LLC | $13.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.